Therefore, it is expected that the inhibition of Ang II via ACEi and/or ARBs would improve portal hypertension not only by attenuating hepatic fibrosis but also by improving intrahepatic resistance to blood flow in cirrhosis [48,103,104]. The gene discussed is AGT; the disease is Hepatic fibrosis.